Literature DB >> 25374910

Prostate cancer progression and metastasis: potential regulatory pathways for therapeutic targeting.

Srinivas Nandana1, Leland Wk Chung2.   

Abstract

Skeletal metastasis in advanced prostate cancer (PCa) patients remains a significant cause of morbidity and mortality. Research utilizing animal models during the past decade has reached a consensus that PCa progression and distant metastasis can be tackled at the molecular level. Although there are a good number of models that have shown to facilitate the study of PCa initiation and progression at the primary site, models that mimic the distant dissemination of cancer cells, particularly bone metastasis, are scarce. Despite this limitation, the field has gleaned valuable knowledge on the underlying molecular mechanisms and pathways of PCa progression, including local invasion and distant metastasis, and has moved forward in developing the concepts of current therapeutic modalities. The purpose of this review is to put together recent work on pathways that are currently being targeted for therapy, as well as other prospective novel therapeutic targets to be developed in the future against metastatic and potentially lethal PCa in patients.

Entities:  

Keywords:  Prostate cancer; metastasis; pathways; progression; therapeutic targeting

Year:  2014        PMID: 25374910      PMCID: PMC4219303     

Source DB:  PubMed          Journal:  Am J Clin Exp Urol        ISSN: 2330-1910


  86 in total

Review 1.  The functions and regulation of the PTEN tumour suppressor.

Authors:  Min Sup Song; Leonardo Salmena; Pier Paolo Pandolfi
Journal:  Nat Rev Mol Cell Biol       Date:  2012-04-04       Impact factor: 94.444

2.  Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2.

Authors:  Daniel Kirchhofer; Mark Peek; Michael T Lipari; Karen Billeci; Bin Fan; Paul Moran
Journal:  FEBS Lett       Date:  2005-03-28       Impact factor: 4.124

3.  Hepsin promotes prostate cancer progression and metastasis.

Authors:  Olga Klezovitch; John Chevillet; Janni Mirosevich; Richard L Roberts; Robert J Matusik; Valeri Vasioukhin
Journal:  Cancer Cell       Date:  2004-08       Impact factor: 31.743

4.  Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications.

Authors:  Gaoping Chen; Nicholas Shukeir; Anil Potti; Kanishka Sircar; Armen Aprikian; David Goltzman; Shafaat A Rabbani
Journal:  Cancer       Date:  2004-09-15       Impact factor: 6.860

5.  Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer.

Authors:  Qianben Wang; Wei Li; Yong Zhang; Xin Yuan; Kexin Xu; Jindan Yu; Zhong Chen; Rameen Beroukhim; Hongyun Wang; Mathieu Lupien; Tao Wu; Meredith M Regan; Clifford A Meyer; Jason S Carroll; Arjun Kumar Manrai; Olli A Jänne; Steven P Balk; Rohit Mehra; Bo Han; Arul M Chinnaiyan; Mark A Rubin; Lawrence True; Michelangelo Fiorentino; Christopher Fiore; Massimo Loda; Philip W Kantoff; X Shirley Liu; Myles Brown
Journal:  Cell       Date:  2009-07-23       Impact factor: 41.582

6.  Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone.

Authors:  Z G Li; J Yang; E S Vazquez; D Rose; F Vakar-Lopez; P Mathew; A Lopez; C J Logothetis; S-H Lin; N M Navone
Journal:  Oncogene       Date:  2007-08-13       Impact factor: 9.867

Review 7.  Modeling prostate cancer in mice: something old, something new, something premalignant, something metastatic.

Authors:  Shazia Irshad; Cory Abate-Shen
Journal:  Cancer Metastasis Rev       Date:  2013-06       Impact factor: 9.264

8.  Prostate tumor progression is mediated by a paracrine TGF-beta/Wnt3a signaling axis.

Authors:  X Li; V Placencio; J M Iturregui; C Uwamariya; A-R Sharif-Afshar; T Koyama; S W Hayward; N A Bhowmick
Journal:  Oncogene       Date:  2008-08-25       Impact factor: 9.867

9.  Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer.

Authors:  Shunyou Wang; Jing Gao; Qunying Lei; Nora Rozengurt; Colin Pritchard; Jing Jiao; George V Thomas; Gang Li; Pradip Roy-Burman; Peter S Nelson; Xin Liu; Hong Wu
Journal:  Cancer Cell       Date:  2003-09       Impact factor: 31.743

10.  Targeted inhibition of cell-surface serine protease Hepsin blocks prostate cancer bone metastasis.

Authors:  Xi Tang; Sumit S Mahajan; Liem T Nguyen; François Béliveau; Richard Leduc; Julian A Simon; Valeri Vasioukhin
Journal:  Oncotarget       Date:  2014-03-15
View more
  15 in total

1.  Micellar Delivery of miR-34a Modulator Rubone and Paclitaxel in Resistant Prostate Cancer.

Authors:  Di Wen; Yang Peng; Feng Lin; Rakesh K Singh; Ram I Mahato
Journal:  Cancer Res       Date:  2017-04-20       Impact factor: 12.701

2.  Rap2B promotes cell proliferation, migration and invasion in prostate cancer.

Authors:  Jiehui Di; Huan Cao; Juangjuan Tang; Zheng Lu; Keyu Gao; Zhesi Zhu; Junnian Zheng
Journal:  Med Oncol       Date:  2016-05-06       Impact factor: 3.064

3.  Prostate cancer: unmet clinical needs and RAD9 as a candidate biomarker for patient management.

Authors:  Howard B Lieberman; Alex J Rai; Richard A Friedman; Kevin M Hopkins; Constantinos G Broustas
Journal:  Transl Cancer Res       Date:  2018-01-14       Impact factor: 1.241

4.  Prevention of prostate cancer by natural product MDM2 inhibitor GS25: in vitro and in vivo activities and molecular mechanisms.

Authors:  Wei Wang; Jiang-Jiang Qin; Xin Li; Guanyu Tao; Qiang Wang; Xuming Wu; Jianwei Zhou; Xiaolin Zi; Ruiwen Zhang
Journal:  Carcinogenesis       Date:  2018-07-30       Impact factor: 4.944

5.  Impact of E6-associated protein on the proliferation and invasion of prostate cancer cells in bone metastasis.

Authors:  Liyan Zhang; Xiaoguang Hu; Jiying Chen; Guilian Fu
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

6.  Metastatic Prostate Cancer to the Left Temporal Bone: A Case Report and Review of the Literature.

Authors:  Erynne A Faucett; Hal Richins; Rihan Khan; Abraham Jacob
Journal:  Case Rep Otolaryngol       Date:  2015-07-30

7.  Decreased expression of SLC 39A14 is associated with tumor aggressiveness and biochemical recurrence of human prostate cancer.

Authors:  Xiao-Ming Xu; Cheng-Gong Wang; Yu-Di Zhu; Wei-Hua Chen; Si-Liang Shao; Fu-Neng Jiang; Qian-De Liao
Journal:  Onco Targets Ther       Date:  2016-07-11       Impact factor: 4.147

8.  MicroRNA-410-5p as a potential serum biomarker for the diagnosis of prostate cancer.

Authors:  Jiaqi Wang; Huamao Ye; Dandan Zhang; Yijun Hu; Xiya Yu; Long Wang; Changjing Zuo; Yongwei Yu; Guixia Xu; Shanrong Liu
Journal:  Cancer Cell Int       Date:  2016-02-19       Impact factor: 5.722

9.  The metabolic co-regulator PGC1α suppresses prostate cancer metastasis.

Authors:  Veronica Torrano; Lorea Valcarcel-Jimenez; Jason W Locasale; Roger R Gomis; Ana Rosa Cortazar; Xiaojing Liu; Jelena Urosevic; Mireia Castillo-Martin; Sonia Fernández-Ruiz; Giampaolo Morciano; Alfredo Caro-Maldonado; Marc Guiu; Patricia Zúñiga-García; Mariona Graupera; Anna Bellmunt; Pahini Pandya; Mar Lorente; Natalia Martín-Martín; James David Sutherland; Pilar Sanchez-Mosquera; Laura Bozal-Basterra; Amaia Zabala-Letona; Amaia Arruabarrena-Aristorena; Antonio Berenguer; Nieves Embade; Aitziber Ugalde-Olano; Isabel Lacasa-Viscasillas; Ana Loizaga-Iriarte; Miguel Unda-Urzaiz; Nikolaus Schultz; Ana Maria Aransay; Victoria Sanz-Moreno; Rosa Barrio; Guillermo Velasco; Paolo Pinton; Carlos Cordon-Cardo; Arkaitz Carracedo
Journal:  Nat Cell Biol       Date:  2016-05-23       Impact factor: 28.824

10.  Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model.

Authors:  Giacomo Canesin; Susan Evans-Axelsson; Rebecka Hellsten; Agnieszka Krzyzanowska; Chandra P Prasad; Anders Bjartell; Tommy Andersson
Journal:  PLoS One       Date:  2017-09-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.